Zai Lab (NASDAQ:ZLAB – Get Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Zai Lab to post earnings of ($0.65) per share and revenue of $108.53 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.
Zai Lab Stock Performance
Shares of ZLAB opened at $30.97 on Thursday. The stock has a 50-day moving average of $26.66 and a two-hundred day moving average of $25.07. Zai Lab has a one year low of $13.48 and a one year high of $36.60. The stock has a market cap of $3.39 billion, a P/E ratio of -11.18 and a beta of 1.02.
Wall Street Analysts Forecast Growth
Separately, Cantor Fitzgerald raised Zai Lab to a “strong-buy” rating in a report on Wednesday, February 5th.
Insider Activity at Zai Lab
In other Zai Lab news, insider Rafael Amado sold 7,583 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $26.28, for a total value of $199,281.24. Following the completion of the transaction, the insider now directly owns 33,834 shares of the company’s stock, valued at approximately $889,157.52. The trade was a 18.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 13.88% of the stock is currently owned by insiders.
About Zai Lab
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
Read More
- Five stocks we like better than Zai Lab
- Options Trading – Understanding Strike Price
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- What is a Special Dividend?
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- What is a buyback in stocks? A comprehensive guide for investors
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.
